An update on PARP inhibitors for the treatment of cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Poly (ADP) ribose polymerase (PARP) inhibitors (PARPi) represent a significant advancement in targeted cancer therapy.
• PARPi have demonstrated notable efficacy in cancers associated with BRCA1/2 gene mutations.

Purpose of the Study:

• To review the scientific rationale and theoretical underpinnings of PARP inhibitors.
• To summarize reported and ongoing clinical trials evaluating PARPi in patients with and without BRCA germline mutations.
• To discuss future therapeutic strategies involving PARPi, including combination therapies and use as radiosensitizers.

Main Methods:

• Review of existing literature on PARP inhibitors.
• Analysis of data from reported and ongoing clinical trials.
• Exploration of preclinical and clinical data for combination therapies.

Main Results:

• PARPi have shown encouraging results in BRCA1/2-mutated cancers.
• Research is expanding to evaluate PARPi in a wider patient population, including non-BRCA mutated individuals.
• Combination strategies with PARPi are being investigated to enhance therapeutic outcomes.

Conclusions:

• PARP inhibitors are a valuable addition to molecularly targeted agents in oncology.
• Further clinical trials are essential to define the optimal role of PARPi, particularly for patients beyond BRCA germline mutation carriers.
• The expanding scope of PARPi suggests a growing therapeutic potential across various cancer types.